TABLE 2.
Simulated dosing regimens, target human pharmacokinetic parameters, and resultant pharmacokinetic data
| Antibiotic | Simulated regimen | Peak (μg/ml) | Elimination half-life (h) | AUC (μg · h/ml)e |
|---|---|---|---|---|
| Ciprofloxacin | ||||
| Target parametersa | 400 mg IV q12h | 4.6 | 4 | 24 |
| Actual (mean ± SD) | 4.0 ± 0.2 | 4.2 ± 0.4 | 30.2 ± 2.6 | |
| Levofloxacin | ||||
| Target parametersb | 500 mg IV q24h | 6.4 | 7 | 54.6 |
| Actual (mean ± SD) | 5.7 ± 0.4 | 7.0 ± 0.3 | 57.7 ± 5.2 | |
| Ampicillin (isolates SP28, SP34, and SP12) | ||||
| Target parametersc | 1 g IV q6h | 50 | 1 | 60 |
| Actual (mean ± SD) | 40.9 ± 6.6 | 0.9 ± 0.1 | 65.1 ± 20.5 | |
| Ampicillin (isolate SP4) | ||||
| Target parametersd | 500 mg IV q6h | 25 | 1 | 30 |
| Actual (mean ± SD) | 10.2 ± 0.8 | 1.3 ± 0.2 | 32.7 ± 4.2 |